The Medical Journal "Nutrition, Metabolism & Cardiovascular Diseases" published a report on October 17, 2017 titled "Acute Renal Failure with Sodium-Glucose-Cotransporter-2 Inhibitors: Analysis of the FDA Adverse Event Report System Database." Of course, Invokana is one of those SGCT2 inhibitors.
The article concludes that according to the FDA reporting system, SGLT2-inhibitors (like Invokana) are associated with serious renal failure. Further, the report find that the above link with renal failures persists even when controlling for diabetes and the FDA warning.
The full report is available here.